ArticleHaematologica2016
Combined CXCR3/CXCR4 measurements are of high prognostic value in chronic lymphocytic leukemia due to negative co-operativity of the receptors.
Abstract readLetter
In one paragraph
Article in Haematologica, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed.
- STAT3 as a Candidate Shared Regulator of the CXCR4/CXCL12 and CXCR5/CXCL13 Homing Axes in Chronic Lymphocytic Leukemia.International journal of molecular sciences · 2026Review
- Human Blood IgAEuropean journal of immunology · 2026Article
- Tonic signaling of the B-cell antigen-specific receptor is a common functional hallmark in chronic lymphocytic leukemia cell phosphoproteomes at early disease stages.Molecular oncology · 2025Article
- B-1 derived anti-Thy-1 B cells in old aged mice develop lymphoma/leukemia with high expression of CD11b and Hamp2 that different from TCL1 transgenic mice.Immunity & ageing : I & A · 2024Article
- CXCR4 overexpression in chronic lymphocytic leukemia associates with poorer prognosis: A prospective, single-center, observational study.Genes and immunity · 2024Observational
- Ibrutinib and the chemotactic lymph node choreography.Haematologica · 2024Article
- Lymphocyte migration and retention properties affected by ibrutinib in chronic lymphocytic leukemia.Haematologica · 2024Article
- B cell receptor signaling and associated pathways in the pathogenesis of chronic lymphocytic leukemia.Frontiers in oncology · 2024Review
- Clarifying the molecular mechanism of tomentosin‑induced antiproliferative and proapoptotic effects in human multiple myeloma via gene expression profile and genetic interaction network analysis.International journal of molecular medicine · 2021Article
- Article
- Shared genomic segment analysis in a large high-risk chronic lymphocytic leukemia pedigree implicatesJournal of translational genetics and genomics · 2021Article
- Macrophage Polarization in Chronic Lymphocytic Leukemia: Nurse-Like Cells Are the Caretakers of Leukemic Cells.Biomedicines · 2020Review
- In Human Visualization of Ibrutinib-Induced CLL Compartment Shift.Cancer immunology research · 2020Article
- MRI and PET/MRI in hematologic malignancies.Journal of magnetic resonance imaging : JMRI · 2020Review
- High CXCR3 on Leukemic Cells DistinguishesJournal of immunology research · 2020Article
- Importance of Crosstalk Between Chronic Lymphocytic Leukemia Cells and the Stromal Microenvironment: Direct Contact, Soluble Factors, and Extracellular Vesicles.Frontiers in oncology · 2020Review
- Targeting of CXCR3 improves anti-myeloma efficacy of adoptively transferred activated natural killer cells.Journal for immunotherapy of cancer · 2019Article
- Abnormalities in chemokine receptor recycling in chronic lymphocytic leukemia.Cellular and molecular life sciences : CMLS · 2019Review
- Article
- Molecular Players in Hematologic Tumor Cell Trafficking.Frontiers in immunology · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Sylvia GanghammerLaboratory for Immunological and Molecular Cancer Research, 3rd Medical Department with Haematology, Medical Oncology, Haemostaseology, Infectiology and Rheumatology, Oncologic Center, Paracelsus Medical University, Salzburg, Austria Salzburg Cancer Research Institute, Austria.
Julia GutjahrLaboratory for Immunological and Molecular Cancer Research, 3rd Medical Department with Haematology, Medical Oncology, Haemostaseology, Infectiology and Rheumatology, Oncologic Center, Paracelsus Medical University, Salzburg, Austria Salzburg Cancer Research Institute, Austria.
Evelyn HuttererLaboratory for Immunological and Molecular Cancer Research, 3rd Medical Department with Haematology, Medical Oncology, Haemostaseology, Infectiology and Rheumatology, Oncologic Center, Paracelsus Medical University, Salzburg, Austria Salzburg Cancer Research Institute, Austria.
Peter W KrennLaboratory for Immunological and Molecular Cancer Research, 3rd Medical Department with Haematology, Medical Oncology, Haemostaseology, Infectiology and Rheumatology, Oncologic Center, Paracelsus Medical University, Salzburg, Austria Salzburg Cancer Research Institute, Austria.
Susanne PucherLaboratory for Immunological and Molecular Cancer Research, 3rd Medical Department with Haematology, Medical Oncology, Haemostaseology, Infectiology and Rheumatology, Oncologic Center, Paracelsus Medical University, Salzburg, Austria Salzburg Cancer Research Institute, Austria.
Claudia Zelle-RieserTyrolean Cancer Research Institute, Innsbruck, Austria.
Karin JöhrerTyrolean Cancer Research Institute, Innsbruck, Austria.
Maikel WijtmansAmsterdam Institute for Molecules, Medicines and Systems (AIMMS), Division Medicinal Chemistry, VU University Amsterdam, the Netherlands.
Rob LeursAmsterdam Institute for Molecules, Medicines and Systems (AIMMS), Division Medicinal Chemistry, VU University Amsterdam, the Netherlands.
Martine J SmitAmsterdam Institute for Molecules, Medicines and Systems (AIMMS), Division Medicinal Chemistry, VU University Amsterdam, the Netherlands.
Valter GatteiClinical and Experimental Onco-Hematology Unit, Centro di Riferimento Oncologico, Aviano, Italy.
Richard GreilLaboratory for Immunological and Molecular Cancer Research, 3rd Medical Department with Haematology, Medical Oncology, Haemostaseology, Infectiology and Rheumatology, Oncologic Center, Paracelsus Medical University, Salzburg, Austria Salzburg Cancer Research Institute, Austria.
Tanja N HartmannLaboratory for Immunological and Molecular Cancer Research, 3rd Medical Department with Haematology, Medical Oncology, Haemostaseology, Infectiology and Rheumatology, Oncologic Center, Paracelsus Medical University, Salzburg, Austria Salzburg Cancer Research Institute, Austria t.hartmann@salk.at.
Funding
Austrian Science Fund FWF P 25015
Abstract
PubMed holds no abstract for this paper.
Indexed as
Gene Expression Regulation, LeukemicAntineoplastic AgentsB-LymphocytesChemokine CXCL10Chemokine CXCL11Chemokine CXCL9ChemotaxisDisease ProgressionHumansImmunophenotypingLeukemia, Lymphocytic, Chronic, B-CellLymphocyte ActivationNiacinamidePiperazinesPredictive Value of TestsPrimary Cell Culture5-chloro-6-(4-(1-(4-chlorobenzyl)piperidin-4-yl)-3-ethylpiperazin-1-yl)-N-ethylnicotinamideAntineoplastic AgentsChemokine CXCL10Chemokine CXCL11Chemokine CXCL9CXCL10 protein, humanCXCL11 protein, humanCXCL9 protein, humanCXCR3 protein, humanCXCR4 protein, humanNiacinamidePiperazinesReceptors, CXCR3Receptors, CXCR4B-cell receptorchemokineCLLCXCL12microenvironment
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.